Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Section 5 of 6

Economic information and modeling report

35 evidence topics · 14 sources

Modeling overview

Summary

The published economic evaluations of HAE prophylaxis collected for this report date from 2018 to 2026, and none evaluates onvuzosiran.

The 2018 ICER final evidence report compared Cinryze, Haegarda, and lanadelumab with no prophylaxis in a Markov model with one-month cycles over a lifetime horizon, from a US health care system perspective with a 3% discount rate. The modeled population had a mean age of 39.6 years, was 68.4% female, and had a baseline rate of 3.39 attacks per month. Against no prophylaxis, the incremental cost-effectiveness ratios were $5,954,000 for Cinryze, $328,000 for Haegarda, and $1,108,000 for lanadelumab, with 0.75, 1.19, and 1.19 QALYs gained. The report concluded that, at the drug prices of 2018, prophylactic treatment “does not meet traditional cost-effectiveness thresholds” in its base case, and that sensitivity analyses produced widely varying findings. Its budget impact analysis of lanadelumab used an annual WAC of $565,557, covered five years without discounting, and reached 13% of the $991 million threshold at WAC.

ICER's 2021 observational real-world evidence update reported incremental costs per QALY gained of $30,070,000 for Cinryze, $13,430,000 for Haegarda, and $12,370,000 for Takhzyro, and states that incremental ratios “can become extreme with small denominators”.

The 2026 NICE draft guidance for England does not recommend donidalorsen. It rests on a company cost-comparison analysis that assumed equal efficacy across long-term prophylactic treatments, and states that the most likely cost-effectiveness estimates for donidalorsen cannot be determined.

The 2018 ICER analysis evaluated the three drugs then approved for long-term prophylaxis of HAE-1/2 (Cinryze, Haegarda, and lanadelumab), and the 2021 ICER update reports results for the same three drugs. No US cost-effectiveness or budget impact analysis of berotralstat, garadacimab, or donidalorsen was identified.

Comparator-treatment economic assessment: observational real-world evidence update

Comparator cost-effectiveness model: base-case incremental results versus no prophylaxis

MeasureCinryzeHaegardaLanadelumab
QALYs gained“0.75”“1.19”“1.19”
Attacks avoided“860”“1,430”“1,480”
Incremental cost-effectiveness ratio, US health system perspective“$5,954,000”“$328,000”“$1,108,000”
Cost per attack avoided, US health system perspective“$5,168”“$273”“$892”

Comparator budget impact analysis: lanadelumab per-patient results

Average annual per-patient budget impactAt WACAt net price
Lanadelumab“$620,338”“$478,464”
Haegarda/Cinryze/no long-term prophylaxis (49%/49%/2%)“$524,192”“$524,192”
Difference“$96,145”“-$45,729”

Estimated annual wholesale acquisition cost of long-term prophylactic agents

ProductEstimated annual WAC
Dawnzera (donidalorsen), every 4 weeks“$747,006”
Andembry (garadacimab)“$685,200”
Orladeyo (berotralstat)“$579,885”
Takhzyro (lanadelumab)“$685,171”
Haegarda (C1 esterase inhibitor, subcutaneous)“$604,152”
Cinryze (C1 esterase inhibitor, intravenous)“$665,224”

Federal Supply Schedule and Big Four prices, November 2026

ProductPackageNDCPrice typePrice ($)
Lanadelumab“TAKHZYRO 150MG/ML INJ,SYRINGE,2ML”“47783-0646-01”“Big4”“19571.48”
Lanadelumab“TAKHZYRO 150MG/ML INJ,SYRINGE,2ML”“47783-0646-01”“FSS”“24975.51”
Lanadelumab“TAKHZYRO 150MG/ML INJ”“47783-0644-01”“Big4”“16482.83”
Lanadelumab“TAKHZYRO 150MG/ML INJ”“47783-0644-01”“FSS”“24973.13”
Berotralstat“ORLADEYO 150MG CAP”“72769-0101-01”“FSS”“30292.93”
Garadacimab“ANDEMBRY 200MG/1.2ML AUTOINJECTOR”“63833-0925-01”“Big4”“42741.79”
Garadacimab“ANDEMBRY 200MG/1.2ML AUTOINJECTOR”“63833-0925-01”“FSS”“56239.20”
Donidalorsen“DAWNZERA 80MG/0.8ML INJ,AUTOINJECTOR”“71860-0103-01”“Big4”“43012.76”
Donidalorsen“DAWNZERA 80MG/0.8ML INJ,AUTOINJECTOR”“71860-0103-01”“FSS”“56595.74”
C1 esterase inhibitor, subcutaneous“HAEGARDA 2000UNITS/VIL INJ,SOLN”“63833-0828-02”“Big4”“1751.37”
C1 esterase inhibitor, subcutaneous“HAEGARDA 2000UNITS/VIL INJ,SOLN”“63833-0828-02”“FSS”“2175.77”
C1 esterase inhibitor, subcutaneous“HAEGARDA 3000UNITS/VIL INJ,SOLN”“63833-0829-02”“Big4”“2627.18”
C1 esterase inhibitor, subcutaneous“HAEGARDA 3000UNITS/VIL INJ,SOLN”“63833-0829-02”“FSS”“3263.65”
C1 esterase inhibitor, intravenous“CINRYZE C-1 INHIBITOR 500IU/VIL”“42227-0083-01”“Big4”“2306.86”
C1 esterase inhibitor, intravenous“CINRYZE C-1 INHIBITOR 500IU/VIL”“42227-0083-01”“FSS”“3122.91”

Medicare Part D spending on long-term prophylactic agents, 2024

BrandTotal spending, 2024 ($)Beneficiaries, 2024Average spending per dosage unit, 2024 ($)Average spending per beneficiary, 2024 ($)
Takhzyro (lanadelumab)“223004902.8”“512”“12775.306747”“435556.45078”
Orladeyo (berotralstat)“77894702.6”“221”“1516.0510432”“352464.71765”
Haegarda (C1 esterase inhibitor)“82014748.23”“187”“2952.876629”“438581.54134”
Cinryze (C1 esterase inhibitor)“33104776.46”“46”“3256.1007633”“719669.05348”

Medicare Part D spending on on-demand agents, 2024

BrandTotal spending, 2024 ($)Beneficiaries, 2024Average spending per dosage unit, 2024 ($)Average spending per beneficiary, 2024 ($)
Firazyr (icatibant)“43713828.6”“170”“3553.9698049”“257140.16824”
Icatibant (generic)“32477428.42”“658”“955.46002803”“49357.793951”
Berinert (C1 esterase inhibitor)“34597556.94”“63”“3904.4754475”“549167.57048”
Ruconest (recombinant C1 esterase inhibitor)“55710878.24”“128”“7557.0914596”“435241.23625”
Kalbitor (ecallantide)“20871584.35”“36”“5624.2480059”“579766.23194”

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.